Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas NCT02323880 Malignant Gliom...
Recurrent Brain...
Recurrent Child...
Recurrent Child...
Recurrent Lymph...
Recurrent Malig...
Refractory Lymp...
Refractory Mali...
Refractory Prim...
WHO Grade 3 Gli...
Pharmacological...
Selinexor
12 Months - 21 Years Children's Oncology Group View Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors NCT02780804 Brain Stem Neop...
Pineal Region N...
Recurrent Lymph...
Recurrent Malig...
Recurrent Prima...
Recurrent Visua...
Refractory Lymp...
Refractory Mali...
Refractory Prim...
Refractory Visu...
Entinostat
Laboratory Biom...
Pharmacological...
12 Months - 21 Years National Cancer Institute (NCI) View Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia NCT03418038 Clonal Cytopeni...
High Grade B-Ce...
Recurrent Diffu...
Recurrent Hodgk...
Recurrent Lymph...
Refractory Diff...
Refractory Lymp...
Chronic Myelomo...
Ascorbic Acid
Carboplatin
Cisplatin
Cytarabine
Dexamethasone
Etoposide
Gemcitabine Hyd...
Ifosfamide
Laboratory Biom...
Oxaliplatin
Placebo Adminis...
Questionnaire A...
Rituximab
Decitabine
Biospecimen Col...
Core Biopsy
Bone Marrow Asp...
Bone Marrow Bio...
Echocardiograph...
Positron Emissi...
Magnetic Resona...
Central Venous ...
Portacath Place...
Computed Tomogr...
18 Years - Mayo Clinic View Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial NCT04320888 Hematopoietic a...
Recurrent Epend...
Recurrent Ewing...
Recurrent Hepat...
Recurrent Histi...
Recurrent Lange...
Recurrent Lymph...
Recurrent Malig...
Recurrent Malig...
Recurrent Malig...
Recurrent Medul...
Recurrent Neuro...
Recurrent Non-H...
Recurrent Osteo...
Recurrent Perip...
Recurrent Rhabd...
Recurrent Rhabd...
Recurrent Soft ...
Recurrent WHO G...
Refractory Epen...
Refractory Ewin...
Refractory Hepa...
Refractory Hist...
Refractory Lang...
Refractory Lymp...
Refractory Mali...
Refractory Mali...
Refractory Mali...
Refractory Medu...
Refractory Neur...
Refractory Non-...
Refractory Oste...
Refractory Peri...
Refractory Rhab...
Refractory Rhab...
Refractory Soft...
Refractory WHO ...
Wilms Tumor
Computed Tomogr...
Magnetic Resona...
Positron Emissi...
Radionuclide Im...
Selpercatinib
X-Ray Imaging
12 Months - 21 Years National Cancer Institute (NCI) View Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study NCT04500548 Constitutional ...
Hematopoietic a...
Lynch Syndrome
Recurrent Lymph...
Recurrent Malig...
Recurrent Neuro...
Recurrent Prima...
Refractory Lymp...
Refractory Mali...
Refractory Neur...
Refractory Prim...
Xeroderma Pigme...
Biospecimen Col...
Ipilimumab
Nivolumab
12 Months - 25 Years National Cancer Institute (NCI) View Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors NCT02780804 Brain Stem Neop...
Pineal Region N...
Recurrent Lymph...
Recurrent Malig...
Recurrent Prima...
Recurrent Visua...
Refractory Lymp...
Refractory Mali...
Refractory Prim...
Refractory Visu...
Entinostat
Laboratory Biom...
Pharmacological...
12 Months - 21 Years National Cancer Institute (NCI) View Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma NCT03323034 Recurrent Lymph...
Recurrent Malig...
Recurrent Prima...
Refractory Lymp...
Refractory Mali...
Refractory Prim...
Irinotecan
Pevonedistat
Temozolomide
6 Months - 21 Years Children's Oncology Group View Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors NCT05071209 Recurrent Alveo...
Recurrent Ewing...
Recurrent Lymph...
Recurrent Malig...
Refractory Alve...
Refractory Ewin...
Refractory Lymp...
Refractory Mali...
Elimusertib
12 Months - 30 Years National Cancer Institute (NCI) View Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours NCT02343718 Recurrent Lymph...
Refractory Lymp...
Solid Tumours
Central Nervous...
Vinblastine
Temsirolimus
1 Year - 18 Years Canadian Cancer Trials Group View Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) NCT02465060 Advanced Lympho...
Advanced Malign...
Bladder Carcino...
Breast Carcinom...
Cervical Carcin...
Colon Carcinoma
Colorectal Carc...
Endometrial Car...
Esophageal Carc...
Gastric Carcino...
Glioma
Head and Neck C...
Hematopoietic a...
Kidney Carcinom...
Liver Carcinoma
Lung Carcinoma
Lymphoma
Malignant Uteri...
Melanoma
Multiple Myelom...
Ovarian Carcino...
Pancreatic Carc...
Prostate Carcin...
Rectal Carcinom...
Recurrent Bladd...
Recurrent Breas...
Recurrent Cervi...
Recurrent Colon...
Recurrent Color...
Recurrent Esoph...
Recurrent Gastr...
Recurrent Gliom...
Recurrent Head ...
Recurrent Liver...
Recurrent Lung ...
Recurrent Lymph...
Recurrent Malig...
Recurrent Melan...
Recurrent Multi...
Recurrent Ovari...
Recurrent Pancr...
Recurrent Prost...
Recurrent Recta...
Recurrent Skin ...
Recurrent Thyro...
Recurrent Uteri...
Refractory Lymp...
Refractory Mali...
Refractory Mult...
Skin Carcinoma
Thyroid Gland C...
Uterine Corpus ...
Adavosertib
Afatinib
Afatinib Dimale...
Binimetinib
Biopsy
Biospecimen Col...
Capivasertib
Computed Tomogr...
Copanlisib
Copanlisib Hydr...
Crizotinib
Cytology Specim...
Dabrafenib
Dabrafenib Mesy...
Dasatinib
Defactinib
Defactinib Hydr...
Echocardiograph...
Erdafitinib
Fexagratinib
Ipatasertib
Laboratory Biom...
Larotrectinib
Larotrectinib S...
Magnetic Resona...
Multigated Acqu...
Nivolumab
Osimertinib
Palbociclib
Pertuzumab
PI3K-beta Inhib...
Radiologic Exam...
Radionuclide Im...
Relatlimab
Sapanisertib
Sunitinib Malat...
Taselisib
Trametinib
Trastuzumab
Trastuzumab Emt...
Ulixertinib
Vismodegib
18 Years - National Cancer Institute (NCI) View Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma NCT03229278 Lymphoma
Metastatic Mali...
Metastatic Mela...
Metastatic Rena...
Recurrent Bladd...
Recurrent Class...
Recurrent Head ...
Recurrent Lymph...
Recurrent Malig...
Recurrent Renal...
Stage III Bladd...
Stage III Lymph...
Stage III Non-S...
Stage III Renal...
Stage III Skin ...
Stage IIIA Non-...
Stage IIIA Skin...
Stage IIIB Non-...
Stage IIIB Skin...
Stage IIIC Skin...
Stage IV Bladde...
Stage IV Lympho...
Stage IV Non-Sm...
Stage IV Renal ...
Stage IV Skin M...
Stage IVA Bladd...
Stage IVB Bladd...
Unresectable He...
Unresectable So...
Enzyme Inhibito...
Laboratory Biom...
Nivolumab
Pembrolizumab
18 Years - Rutgers, The State University of New Jersey View Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas NCT02323880 Malignant Gliom...
Recurrent Brain...
Recurrent Child...
Recurrent Child...
Recurrent Lymph...
Recurrent Malig...
Refractory Lymp...
Refractory Mali...
Refractory Prim...
WHO Grade 3 Gli...
Pharmacological...
Selinexor
12 Months - 21 Years Children's Oncology Group View Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas NCT02323880 Malignant Gliom...
Recurrent Brain...
Recurrent Child...
Recurrent Child...
Recurrent Lymph...
Recurrent Malig...
Refractory Lymp...
Refractory Mali...
Refractory Prim...
WHO Grade 3 Gli...
Pharmacological...
Selinexor
12 Months - 21 Years Children's Oncology Group View Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment NCT01790152 Hodgkin Lymphom...
Leukemia in Rem...
Lymphoblastic L...
Osteosarcoma
Recurrent Leuke...
Recurrent Lymph...
Recurrent Malig...
Assessment of T...
Laboratory Biom...
Quality-of-Life...
Questionnaire A...
- Children's Oncology Group View CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma NCT04870944 Diffuse Midline...
Metastatic Mali...
Recurrent Diffu...
Recurrent Lymph...
Recurrent Malig...
Recurrent Osteo...
Recurrent Prima...
Refractory Lymp...
Refractory Mali...
Refractory Oste...
Refractory Prim...
Biospecimen Col...
Bone Marrow Asp...
Bone Marrow Bio...
Echocardiograph...
FACT Complex-ta...
12 Months - 30 Years Children's Oncology Group View Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia NCT03418038 Clonal Cytopeni...
High Grade B-Ce...
Recurrent Diffu...
Recurrent Hodgk...
Recurrent Lymph...
Refractory Diff...
Refractory Lymp...
Chronic Myelomo...
Ascorbic Acid
Carboplatin
Cisplatin
Cytarabine
Dexamethasone
Etoposide
Gemcitabine Hyd...
Ifosfamide
Laboratory Biom...
Oxaliplatin
Placebo Adminis...
Questionnaire A...
Rituximab
Decitabine
Biospecimen Col...
Core Biopsy
Bone Marrow Asp...
Bone Marrow Bio...
Echocardiograph...
Positron Emissi...
Magnetic Resona...
Central Venous ...
Portacath Place...
Computed Tomogr...
18 Years - Mayo Clinic View Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment. NCT01022996 Hodgkin Lymphom...
Everolimus (RAD...
18 Years - Novartis View Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors NCT02780804 Brain Stem Neop...
Pineal Region N...
Recurrent Lymph...
Recurrent Malig...
Recurrent Prima...
Recurrent Visua...
Refractory Lymp...
Refractory Mali...
Refractory Prim...
Refractory Visu...
Entinostat
Laboratory Biom...
Pharmacological...
12 Months - 21 Years National Cancer Institute (NCI) View CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma NCT04870944 Diffuse Midline...
Metastatic Mali...
Recurrent Diffu...
Recurrent Lymph...
Recurrent Malig...
Recurrent Osteo...
Recurrent Prima...
Refractory Lymp...
Refractory Mali...
Refractory Oste...
Refractory Prim...
Biospecimen Col...
Bone Marrow Asp...
Bone Marrow Bio...
Echocardiograph...
FACT Complex-ta...
12 Months - 30 Years Children's Oncology Group View Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment. NCT01022996 Hodgkin Lymphom...
Everolimus (RAD...
18 Years - Novartis View Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours NCT02343718 Recurrent Lymph...
Refractory Lymp...
Solid Tumours
Central Nervous...
Vinblastine
Temsirolimus
1 Year - 18 Years Canadian Cancer Trials Group View